Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin�s lymphoma (NHL) in adults. Even if the\r\nnatural history of DLBCL has been improved with the advent of immunochemotherapy, the survival results obtained with current\r\ntreatment options clearly indicate that new agents or novel approaches are needed. Lenalidomide (Revlimid, Celgene Corporation,\r\nSummit, NJ, USA), an analogue of thalidomide, is an immunomodulatory drug with pleiotropic mechanisms of action potentially\r\nadding to immunochemotherapy. We present here the biological rational for the use of lenalidomide in DLBCL in light of recent\r\nadvances in the pathophysiology of the disease and the therapeutic results of the most recent trials published in literature or\r\nreported in meetings in relapsed/refractory situations as well as in first-line treatment.
Loading....